Biosite and Oxford Genome Sciences Announce Collaboration in Colorectal Cancer
News Apr 04, 2006
Biosite® Incorporated and privately-held Oxford Genome Sciences (UK) Ltd. (OGeS) have announced a collaboration for the evaluation of protein-based disease markers for colorectal cancer.
The markers could be used for the development of potential blood-based diagnostic products aimed at expanding personalized therapeutic options for colorectal cancer.
In particular, these blood-based diagnostics would be designed to enable the early identification of colorectal cancer patients that have relapsed, thus enabling clinicians to select the most appropriate therapeutic option.
Today, the fecal occult blood test and colonoscopy, a highly invasive procedure, are the most frequently used screening and diagnostic methods for colorectal cancer, which has a 30 to 40 percent recurrence rate within an average of 18 months after primary diagnosis.
OGeS has developed a database (the Oxford Genome Anatomy Project or OGAP(R)) that integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases.
Under the terms of the collaboration, OGeS will identify at least 25 proteins discovered in blood and tissue samples from relapsing colorectal cancer patients and Biosite will have the rights to develop blood-based diagnostic tests using one or more of those biomarkers.
"We are increasingly interested in studying selected areas of cancer that can benefit from rapid, effective, non-invasive diagnostic technologies," said Kim Blickenstaff, Biosite's chairman and chief executive officer.
"This collaboration expands our research aimed at evaluation of diagnostic tools for relapsing colorectal cancer by providing us with access to high quality validation of potentially valuable protein biomarkers."
"Relapsing disease is the major cause of suffering and death in colorectal cancer patients and there is a complete lack of clinical tools to aid physicians in the process of deciding whom to treat when and whether to treat with chemotherapy," said Christian Rohlff, OGeS' chief executive officer.
"This collaboration with Biosite underpins our corporate objective of applying new strategies to the emerging field of personalized medicine in oncology to improve patient outcomes."
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018